SHMT1基因启动子甲基化与缺血性卒中相关

基础医学与临床 ›› 2020, Vol. 40 ›› Issue (4): 451-455.

SHMT1基因启动子甲基化与缺血性卒中相关

胡景岑¹, 李链¹, 王淑瑜¹, 许磊¹, 杨德伦¹, 韩丽媛^1*, 许国栋^1,2*

1.宁波大学浙江省病理生理学技术研究重点实验室, 浙江宁波 315211;
2.宁波市医疗中心李惠利医院病案室, 浙江宁波 315211

收稿日期:2019-10-15 修回日期:2020-01-02 出版日期:2020-04-05 发布日期:2020-04-06
通讯作者: *hanliyuan@nbu.edu.cn; 18815281025@163.com
基金资助:
国家自然科学基金(81402745);浙江省自然科学基金(LY17H260002);浙江省大学生科技创新活动计划(2018R405092)

Association between SHMT1 gene promoter methylation and ischemic stroke

HU Jing-cen¹, LI Lian¹, WANG Shu-yu¹, XU Lei¹, YANG De-lun¹, HAN Li-yuan^1*, XU Guo-dong^1,2*

1. Zhejiang Key Laboratory of Pathophysiology Technological Research, Ningbo University, Ningbo 315211;
2. Medical Record Statistics Room, Ningbo Medical Center Lihuili Hospital, Ningbo 315211, China

Received:2019-10-15 Revised:2020-01-02 Online:2020-04-05 Published:2020-04-06
Contact: *hanliyuan@nbu.edu.cn; 18815281025@163.com

摘要/Abstract

摘要： 目的探究丝氨酸羟甲基转移酶(SHMT1)基因甲基化与缺血性卒中的关系。方法采用甲基化特异性实时定量PCR测定290名健康对照组和141例缺血性卒中病例组(卒中组)的SHMT1甲基化水平。结果卒中组SHMT1甲基化水平为24.87% (16.97~35.46)高于对照组的6.58 % (2.43~15.14) (P＜0.05)。在调整相关危险因素后, SHMT1甲基化是卒中的危险因素(OR=1.051, 95% CI=1.034~1.068)。受试者工作特征曲线下面积为0.804,95% CI=0.760~0.849 (P＜0.01)。在对照组发现尿酸与SHMT1甲基化相关(r_s=0.17,P＜0.01),在卒中组发现三酰甘油与SHMT1甲基化相关 (r_s=0.18,P＜0.05)。SHMT1甲基化表达与mRNA的表达呈负相关(r=-0.472,P＜0.01)。结果缺血性卒中患者中SHMT1基因启动子呈高甲基化状态, SHMT1低表达,且SHMT1高甲基化是卒中的危险因素。

关键词: 缺血性卒中, 丝氨酸羟甲基转移酶1, DNA启动子, 甲基化

Abstract: Objective To explore the relationship between serine hydroxymethyltransferase (SHMT1) gene methylation and ischemic stroke patients. Methods The quantitative methylation-specific PCR was used to measure the level of SHMT1 promoter methylation in 290 healthy control individuals and 141 ischemic stroke patients. Results The results showed that the SHMT1 methylation level in the stroke group was 24.87(16.97~35.46), higher than that in the control group 6.58(2.43~15.14) (P＜0.05). After adjusting for relevant risk factors, SHMT1 methylation was a risk factor for stroke(OR=1.051, 95% CI= 1.034~1.068). Area under the curve was 0.804, 95% CI=0.760~0.849(P＜0.01). The level of uric acid was associated with SHMT1 methylation in the control group(r_s=0.17, P＜0.01), and the level of TG was associated with SHMT1 methylation in the stroke group(r_s=0.18, P＜0.05). SHMT1 methylation expression was negatively correlated with mRNA expression(r=-0.472, P＜0.01). Conclusions The SHMT1 gene is more methylated and results in low expression in ischemic stroke patients, so SHMT1 hypermethylation is a risk factor for stroke.

Key words: ischemic stroke, serine hydroxymethyltransferase 1, DNA promoter, methylation

中图分类号:

R394.3

胡景岑, 李链, 王淑瑜, 许磊, 杨德伦, 韩丽媛, 许国栋. SHMT1基因启动子甲基化与缺血性卒中相关[J]. 基础医学与临床, 2020, 40(4): 451-455.

HU Jing-cen, LI Lian, WANG Shu-yu, XU Lei, YANG De-lun, HAN Li-yuan, XU Guo-dong. Association between SHMT1 gene promoter methylation and ischemic stroke[J]. Basic & Clinical Medicine, 2020, 40(4): 451-455.

参考文献

[1]Strozynska E, Fiszer U, Ryglewicz D, et al. The impact of risk burden differences between men and women on the clinical course of ischemic stroke[J]. J Stroke Cerebrovasc Dis, 2016, 25:843-847.
[2]Satyaki PR, Gehring M. DNA methylation and imprinting in plants: machinery and mechanisms[J]. Crit Rev Biochem Mol Biol, 2017, 52:163-175.
[3]Baccarelli A, Wright R, Bollati V, et al. Ischemic heart disease and stroke in relation to blood DNA methylation[J]. Epidemiology, 2010, 21:819-828.
[4]Stam J. Thrombosis of the cerebral veins and sinuses[J]. N Engl J Med, 2005,352:1791-1798.
[5]Dong C, Yoon W, Goldschmidt-clermont PJ. DNA methylation and atherosclerosis[J]. J Nutr, 2002, 132:2406s-2409s.
[6]Hiltunen MO, Yla-herttuala S. DNA methylation, smooth muscle cells, and atherogenesis[J]. Arterioscler Thromb Vasc Biol, 2003, 23:1750-1753.
[7]Valentin F, Bueb JL, Kieffer P, et al. Oxidative stress activates MMP-2 in cultured human coronary smooth muscle cells[J]. Fundam Clin Pharmacol, 2005, 19:661-667.
[8]Boehme B, Schelski N, Makridakis M, et al. Role of cytosolic serine hydroxymethyl transferase 1 (SHMT1) in phosphate-induced vascular smooth muscle cell calcifica-tion[J]. Kidney Blood Press Res, 2018, 43:1212-1221.
[9]Jiang D, Zheng D, Wang L, et al. Elevated PLA2G7 gene promoter methylation as a gender-specific marker of aging increases the risk of coronary heart disease in females[J]. PLoS One, 2013, 8: e59752. doi: 10.1371/journal.pone.0059752.
[10]Sebag IA, Gillis MA, Calderone A, et al. Sex hormone control of left ventricular structure/function: mechanistic insights using echocardiography, expression, and DNA methylation analyses in adult mice[J]. Am J Physiol Heart Circ Physiol, 2011, 301: H1706-1715.
[11]Hsiung DT, Marsit CJ, Houseman EA, et al. Global DNA methylation level in whole blood as a biomarker in head and neck squamous cell carcinoma[J]. Cancer Epidemiol Biomarkers Prev, 2007, 16: 108-114.
[12]Zhang FF, Cardarelli R, Carroll J, et al. Significant differences in global genomic DNA methylation by gender and race/ethnicity in peripheral blood[J]. Epigenetics, 2011, 6: 623-629.
[13]Low HQ, Chen CP, Kasiman K, et al. A comprehensive association analysis of homocysteine metabolic pathway genes in Singaporean Chinese with ischemic stroke[J]. PLoS One, 2011, 6: e24757. doi: 10.1371/journal.pone.0024757.
[14]Xu G, Wang C, Ying X, et al. Serine hydroxymethyltransferase 1 promoter hypermethylation increases the risk of essential hypertension[J]. J Clin Lab Anal, 2019, 33: e22712. doi: 10.1002/jcla.22712.

[1]	卢慧莹, 王建国. 下调去甲基化酶FTO抑制人肝癌细胞系HepG2增殖[J]. 基础医学与临床, 2024, 44(2): 185-191.
[2]	冯雪岩, 熊云云, 王利圆, 曹智鑫, 郝曼均, 宗黎霞, 王上. 颅外动脉狭窄不同干预方案联合机械取栓治疗前循环串联病变的再灌注效果[J]. 基础医学与临床, 2024, 44(10): 1388-1393.
[3]	陈辛, 陈俊, 徐幸, 王旭. 组蛋白去甲基化酶抑制剂GSK-J4减轻高脂诱导的肥胖小鼠体质量[J]. 基础医学与临床, 2023, 43(9): 1353-1358.
[4]	韩晶晶, 王萱若, 张欣怡, 高涵, 成秀梅, 杨留才, 曲学彬. 转录因子CREB调节小鼠CD4⁺淋巴细胞中miR-30a的表达[J]. 基础医学与临床, 2023, 43(8): 1229-1233.
[5]	薛剑超, 王亚东, 李博文, 刘新宇, 梁乃新, 李单青. DNA甲基化在肺癌发生及预后中作用的研究进展[J]. 基础医学与临床, 2023, 43(3): 514-518.
[6]	李雨喋, 王宏宇, 韩松, 李俊发. 激活素A通过少突胶质细胞ACVR1C改善缺血性卒中小鼠神经功能的预后[J]. 基础医学与临床, 2023, 43(3): 380-385.
[7]	刘东, 李庆妍, 王自全, 王丙武, 王保庆. 胃癌患者外周血miR-34a甲基化的检测及临床意义[J]. 基础医学与临床, 2023, 43(10): 1572-1576.
[8]	杨晓菲, 李强, 李延峰, 王洪权. 靶向Nrf2/ARE通路治疗缺血性卒中的研究进展[J]. 基础医学与临床, 2023, 43(1): 169-173.
[9]	郑婧婧, 卜宁, 赵钊, 张佳靖, 于慧, 赵宇航. 心肌肥大表观遗传调控的研究进展[J]. 基础医学与临床, 2022, 42(3): 520-524.
[10]	陈凤, 冷玉芳, 任以行, 张健民, 刘馨, 石亚静. 表观遗传调控在阻塞性睡眠呼吸暂停综合征中的作用研究进展[J]. 基础医学与临床, 2021, 41(6): 899-903.
[11]	孙静瑶, 佟伟民, 牛亚梅. mRNA转录后调控异常在阿尔茨海默病发病机制中的研究进展[J]. 基础医学与临床, 2021, 41(5): 749-752.
[12]	李冉, 郝延磊. mRNA甲基化与疾病的研究进展[J]. 基础医学与临床, 2021, 41(11): 1671-1679.
[13]	王迪, 李晴, 佟伟民, 牛亚梅. 胆管癌中异柠檬酸脱氢酶基因突变潜在靶基因的鉴定[J]. 基础医学与临床, 2020, 40(4): 512-517.
[14]	董保龙, 韩彩文, 史明, 郑文学, 杨晓军. 波形蛋白在肝细胞癌中的研究进展[J]. 基础医学与临床, 2020, 40(2): 238-242.
[15]	蔡波, 邢娟娟, 胡蓉, 任欣, 王榕, 吴恬宁, 郭菲, 陈少卿. 组蛋白H3K27甲基化对人高分化鼻咽癌细胞系CNE-1增殖的抑制效应[J]. 基础医学与临床, 2020, 40(12): 1613-1618.